Infant Metabolome in Relation to Prenatal DHA Supplementation and Maternal Single-Nucleotide Polymorphism rs174602: Secondary Analysis of a Randomized Controlled Trial in Mexico. Issue 11 (7th September 2021)

• Record Type: Journal Article
• Authors: Tandon, Sonia; Gonzalez-Casanova, Ines; Barraza-Villarreal, Albino; Romieu, Isabelle; Demmelmair, Hans; Jones, Dean P; Koletzko, Berthold; Stein, Aryeh D; Ramakrishnan, Usha
• Is Part Of: Journal of nutrition. Volume 151:Issue 11(2021)
• Page Start: 3339
• Page End: 3349
• Publication Date: 2021-09-07
• Subjects: DHA -- prenatal supplementation -- FADS -- SNPs -- untargeted metabolomics -- Mexico; Nutrition -- Periodicals; Diet -- Periodicals; 613.205
• DOI: 10.1093/jn/nxab276
• Languages: English
• ISSNs: 0022-3166

Abstract

ABSTRACT: Background: Although DHA (22:6n–3) is critical for fetal development, results from randomized controlled trials (RCTs) of prenatal DHA supplementation report inconsistent effects on offspring health. Variants in fatty acid desaturase ( FADS ) genes that regulate the conversion of n–3 and n–6 essential fatty acids into their biologically active derivatives may explain this heterogeneity. Objectives: We investigated the effect of prenatal DHA supplementation on the offspring metabolome at age 3 mo and explored differences by maternal FADS single-nucleotide polymorphism (SNP) rs174602. Methods: Data were obtained from a double-blind RCT in Mexico [POSGRAD (Prenatal Omega-3 Fatty Acid Supplementation and Child Growth and Development)] in which women (18–35 y old) received DHA (400 mg/d) or placebo from mid-gestation until delivery. Using high-resolution MS with LC, untargeted metabolomics was performed on 112 offspring plasma samples. Discriminatory metabolic features were selected via linear regression ( P < 0.05) with false discovery rate (FDR) correction ( q = 0.2). Interaction by SNP rs174602 was assessed using 2-factor ANOVA. Stratified analyses were performed, where the study population was grouped into carriers (TT, TC; n = 70) and noncarriers (CC; n = 42) of the minor allele. Pathway enrichment analysis was performed with Mummichog ( P < 0.05). Results: After FDR correction, there were no differences in metabolic features between infants whose mothers received prenatal DHA ( n = 58) and those whose mothers received placebo ( n = 54). However, we identified 343 differentially expressed features in the interaction analysis after FDR correction. DHA supplementation positively enriched amino acid and aminosugars metabolism pathways and decreased fatty acid metabolism pathways among offspring of minor allele carriers and decreased metabolites within the tricarboxylic acid cycle and galactose metabolism pathways among offspring of noncarriers. Conclusions: Our findings demonstrate differences in infant metabolism in response to prenatal DHA supplementation by maternal SNP rs174602 and further support the need to incorporate genetic analysis of FADS polymorphisms into DHA supplementation trials. This trial was registered at clinicaltrials.gov as NCT00646360.